Compare SSRM & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSRM | BLCO |
|---|---|---|
| Founded | 1946 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Precious Metals | Ophthalmic Goods |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 7.1B |
| IPO Year | 1997 | 2022 |
| Metric | SSRM | BLCO |
|---|---|---|
| Price | $27.07 | $21.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 15 |
| Target Price | ★ $40.25 | $21.71 |
| AVG Volume (30 Days) | ★ 2.3M | 972.7K |
| Earning Date | 11-03-2026 | 10-28-2026 |
| Dividend Yield | ★ 0.21% | N/A |
| EPS Growth | ★ 243.41 | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | $1,629,637,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | $29.97 | $7.83 |
| Revenue Next Year | $8.41 | $5.90 |
| P/E Ratio | $82.29 | ★ N/A |
| Revenue Growth | ★ 63.68 | 6.47 |
| 52 Week Low | $19.69 | $14.44 |
| 52 Week High | $39.44 | $21.40 |
| Indicator | SSRM | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 38.92 | 72.51 |
| Support Level | $24.85 | $15.30 |
| Resistance Level | $28.74 | $21.36 |
| Average True Range (ATR) | 1.26 | 0.74 |
| MACD | 0.15 | 0.19 |
| Stochastic Oscillator | 36.28 | 94.88 |
SSR Mining Inc is a minerals company focused on mining precious metals in the Americas. More than half of Silver Standard's revenue is attributable to the production of gold, with a key portion derived from silver production. The company owns and operates the Marigold mine in Nevada, United States; the Seabee Gold Operation in Saskatchewan, Canada; and the Puna mine in Argentina. The majority of gold production is derived from the Marigold mine, and Silver Standard's silver production is principally derived from the Puna mine.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes brands like Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, and surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xiidra and Miebo that treat various eye complications.